1.81
-0.07(-3.72%)
Currency In USD
| Previous Close | 1.88 |
| Open | 1.95 |
| Day High | 1.98 |
| Day Low | 1.77 |
| 52-Week High | 4.34 |
| 52-Week Low | 1.41 |
| Volume | 1.83M |
| Average Volume | 1.48M |
| Market Cap | 69.62M |
| PE | -2.97 |
| EPS | -0.61 |
| Moving Average 50 Days | 2.97 |
| Moving Average 200 Days | 2.09 |
| Change | -0.07 |
If you invested $1000 in Gain Therapeutics, Inc. (GANX) since IPO date, it would be worth $148.36 as of January 18, 2026 at a share price of $1.81. Whereas If you bought $1000 worth of Gain Therapeutics, Inc. (GANX) shares 3 years ago, it would be worth $487.87 as of January 18, 2026 at a share price of $1.81.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week
GlobeNewswire Inc.
Jan 07, 2026 12:00 PM GMT
BETHESDA, Md., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule the
Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287
GlobeNewswire Inc.
Jan 06, 2026 12:00 PM GMT
Results to be discussed in KOL event today at 10 a.m. ETBETHESDA, Md., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development
Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson’s Disease
GlobeNewswire Inc.
Dec 18, 2025 12:00 PM GMT
Results showed CNS target engagement with reduction in GCase substrate glucosylsphingosine (GluSph) in cerebrospinal fluid (CSF), a prespecified endpoint The reduction in GluSph in CSF, a first-ever observation following the administration of a GCase